Lexaria Bioscience (CSE:LXX-OTCQX:LXRP) President John Docherty joined Steve Darling from Proactive Investors Vancouver to talk about a recent controlled, double-blinded European human clinical study that evaluated TurboCBD, Lexaria’s DehydraTECH powered, cannabidiol fortified hemp-oil capsule.
Docherty told Proactive the parameters of the study and some of the impressive results. He also discussed 2019 and what this study and potentially others will do for the company and their licensing of the technology.
CSE:LXX
Market: CSE
Market Cap: $52.47 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Buds & Duds: Cannabis stocks hold steady; Lexaria rises on amended agreement...
The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, inched 0.2% higher at 122.9 points. Elsewhere, the OTCQX Cannabis index lost 0.2% to 489.3 points. Buds today are Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), Curaleaf Holdings Inc...
1 week, 5 days ago
2 min read
Prev article
2 min read